The importance of PU.1 concentration in hematopoietic lineage commitment and maturation

Blood Cells, Molecules, and Diseases

Volumn 31, Issue 2, 2003, Pages 229-233

  Dahl, Richard ^a   Simon, M Celeste ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PU 1; BIOLOGICAL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; B LYMPHOCYTE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL FATE; CELL LINEAGE; CELL MATURATION; CELL SPECIFICITY; CONCENTRATION RESPONSE; GRANULOCYTE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; TRANSACTIVATION; UPREGULATION; CELL COMPOSITION; CONCENTRATION (PARAMETERS); HUMAN CELL; PROTEIN FUNCTION;

EID: 0347383861     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-9796(03)00152-9     Document Type: Article

References (42)

1. Orkin S.H. Diversification of haematopoietic stem cells to specific lineages. Nat. Rev. Genet. 1:2000;57-64.
2. Cantor A.B., Orkin S.H. Hematopoietic development a balancing act . Curr. Opin. Genet. Dev. 11:2001;513-519.
3. McNagny K., Graf T. Making eosinophils through subtle shifts in transcription factor expression. J. Exp. Med. 195:2002;F43-F47.
4. Hromas R., Orazi A., Neiman R.S., Maki R., Van Beveran C., Moore J., Klemsz M. Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1. Blood. 82:1993;2998-3004.
5. Scott E.W., Simon M.C., Anastasi J., Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science. 265:1994;1573-1577.
6. McKercher S.R., Torbett B.E., Anderson K.L., Henkel G.W., Vestal D.J., Baribault H., Klemsz M., Feeney A.J., Wu G.E., Paige C.J., Maki R.A. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 15:1996;5647-5658.
7. Yamada T., Abe M., Higashi T., Yamamoto H., Kihara-Negishi F., Sakurai T., Shirai T., Oikawa T. Lineage switch induced by overexpression of Ets family transcription factor PU.1 in murine erythroleukemia cells. Blood. 97:2001;2300-2307.
8. Anderson M.K., Weiss A.H., Hernandez-Hoyos G., Dionne C.J., Rothenberg E.V. Constitutive expression of PU.1 in fetal hematopoietic progenitors blocks Tcell development at the pro-T cell stage. Immunity. 16:2002;285-296.
9. DeKoter R.P., Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science. 288:2000;1439-1441.
10. McIvor Z., Hein S., Fiegler H., Schroeder T., Stocking C., Just U., Cross M. Transient expression of PU.1 commits multipotent progenitors to a myeloid fate whereas continued expression favors macrophage over granulocyte differentiation. Exp Hematol. 31:2003;39-47.
11. Courey A.J., Huang J.D. The establishment and interpretation of transcription factor gradients in the Drosophila embryo. Biochim. Biophys. Acta. 1261:1995;1-18.
12. Niwa H., Miyazaki J., Smith A.G. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat. Genet. 24:2000;372-376.
13. Dasen J.S., Rosenfeld M.G. Signaling and transcriptional mechanisms in pituitary development. Annu. Rev. Neurosci. 24:2001;327-355.
14. Scully K.M., Rosenfeld M.G. Pituitary development regulatory codes inmammalian organogenesis . Science. 295:2002;2231-2235.
15. Dasen J.S., O'Connell S.M., Flynn S.E., Treier M., Gleiberman A.S., Szeto D.P., Hooshmand F., Aggarwal A.K., Rosenfeld M.G. Reciprocal interactions of Pit1 and GATA2 mediate signaling gradient-induced determination of pituitary cell types. Cell. 97:1999;587-598.
16. Nerlov C., Querfurth E., Kulessa H., Graf T. GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription. Blood. 95:2000;2543-2551.
17. Zhang P., Zhang X., Iwama A., Yu C., Smith K.A., Mueller B.U., Narravula S., Torbett B.E., Orkin S.H., Tenen D.G. PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. Blood. 96:2000;2641-2648.
18. Zhang P., Behre G., Pan J., Iwama A., Wara-Aswapati N., Radomska H.S., Auron P.E., Tenen D.G., Sun Z. Negative cross-talk between hematopoietic regulators GATA proteins repress PU.1 . Proc. Natl. Acad. Sci. USA. 96:1999;8705-8710.
19. Rekhtman N., Radparvar F., Evans T., Skoultchi A.I. Direct interaction of hematopoietic transcription factors PU.1 and GATA-1 functional antagonism in erythroid cells . Genes Dev. 13:1999;1398-1411.
20. Pevny L., Simon M.C., Robertson E., Klein W.H., Tsai S.F., D'Agati V., Orkin S.H., Costantini F. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature. 349:1991;257-260.
21. Shivdasani R.A., Fujiwara Y., McDevitt M.A., Orkin S.H. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 16:1997;3965-3973.
22. Migliaccio A.R., Rana R.A., Sanchez M., Lorenzini R., Centurione L., Bianchi L., Vannucchi A.M., Migliaccio G., Orkin S.H. GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1 low mouse mutant. J. Exp. Med. 197:2003;281-296.
23. Yu C., Cantor A.B., Yang H., Browne C., Wells R.A., Fujiwara Y., Orkin S.H. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J. Exp. Med. 195:2002;1387-1395.
24. Nutt S.L., Urbanek P., Rolink A., Busslinger M. Essential functions of Pax5 (BSAP) in pro-B cell development difference between fetal and adult B lymphopoiesis and reduced V-to-DJ recombination at the IgH locus . Genes Dev. 11:1997;476-491.
25. Nutt S.L., Heavey B., Rolink A.G., Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature. 401:1999;556-562.
26. Maitra S., Atchison M. BSAP can repress enhancer activity by targeting PU.1 function. Mol. Cell. Biol. 20:2000;1911-1922.
27. Chiang M.Y., Monroe J.G. BSAP/Pax5A expression blocks survival and expansion of early myeloid cells implicating its involvement in maintaining commitment to the B-lymphocyte lineage. Blood. 94:1999;3621-3632.
28. Zhang D.E., Zhang P., Wang N.D., Hetherington C.J., Darlington G.J., Tenen D.G. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc. Natl. Acad. Sci. USA. 94:1997;569-574.
29. Reddy V.A., Iwama A., Iotzova G., Schulz M., Elsasser A., Vangala R.K., Tenen D.G., Hiddemann W., Behre G. Granulocyte inducer C/EBPalpha inactivates the myeloid master regulator PU.1 possible role in lineage commitment decisions . Blood. 100:2002;483-490.
30. Shibata Y., Berclaz P.Y., Chroneos Z.C., Yoshida M., Whitsett J.A., Trapnell B.C. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity. 15:2001;557-567.
31. Panopoulos A.D., Bartos D., Zhang L., Watowich S.S. Control of myeloid-specific integrin alpha Mbeta 2 (CD11b/CD18) expression by cytokines is regulated by Stat3-dependent activation of PU.1. J. Biol. Chem. 277:2002;19001-19007.
32. Bjerregaard M.D., Jurlander J., Klausen P., Borregaard N., Cowland J.B. The in vivo profile of transcription factors during neutrophil differentiation in human bone marrow. Blood. 101:2003;4322-4332.
33. Scandura J.M., Boccuni P., Cammenga J., Nimer S.D. Transcription factor fusions in acute leukemia variations on a theme . Oncogene. 21:2002;3422-3444.
34. Mueller B.U., Pabst T., Osato M., Asou N., Johansen L.M., Minden M.D., Behre G., Hiddemann W., Ito Y., Tenen D.G. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood. 100:2002;998-1007.
35. Lamandin C., Sagot C., Roumier C., Lepelley P., De Botton S., Cosson A., Fenaux P., Preudhomme C. Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? Blood. 100:2002;4680-4681.
36. Vegesna V., Takeuchi S., Hofmann W.K., Ikezoe T., Tavor S., Krug U., Fermin A.C., Heaney A., Miller C.W., Koeffler H.P. C/EBP-beta, C/EBP-delta, PU.1, AML1 genes mutational analysis in 381 samples of hematopoietic and solid malignancies . Leuk. Res. 26:2002;451-457.
37. Friedman A.D. Transcriptional regulation of granulocyte and monocyte development. Oncogene. 21:2002;3377-3390.
38. Vangala R.K., Heiss-Neumann M.S., Rangatia J.S., Singh S.M., Schoch C., Tenen D.G., Hiddemann W., Behre G. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood. 29:2002;29.
39. Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N., Downing J.R., Meyers S., Hiebert S.W. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol. 21:2001;6470-6483.
40. Mizuki M., Fenski R., Halfter H., Matsumura I., Schmidt R., Muller C., Gruning W., Kratz-Albers K., Serve S., Steur C., Buchner T., Kienast J., Kanakura Y., Berdel W.E., Serve H. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 96:2000;3907-3914.
41. Hayakawa F., Towatari M., Kiyoi H., Tanimoto M., Kitamura T., Saito H., Naoe T. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 19:2000;624-631.
42. Mizuki M., Schwaeble J., Steur C., Choudhary C., Agrawal S., Sargin B., Steffen B., Matsumura I., Kanakura Y., Boehmer F.D., Mueller-Tidow C., Berdel W.E., Serve H. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood. 5:2002;5.